Cypros Pharmaceutical Corp. receives Phase I SBIR grant from NIH for development of new class of brain injury drugs.CARLSBAD, Calif.--(BUSINESS WIRE)--March 5, 1997--Cypros Pharmaceutical Corp. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :CYPR) Wednesday announced that it has received a Small Business Innovation Research (SBIR SBIR Small Business Innovation Research (program/grant) SBIR Space Based Infra-Red SBIR Speaker-Boundary Interference SBIR Site Backsurface-referenced Ideal Plane/Range (silicon wafers) ) grant from the National Institutes of Health (NIH "Not invented here." See digispeak. NIH - The United States National Institutes of Health. ) to fund the development of a class of drugs referred to as glial glial /gli·al/ (gli´'l) of or pertaining to the neuroglia. glial of or pertaining to glia or neuroglia. glial limitans a dense network of glial processes at the pia mater. chloride channel blockers. Cypros scientists have shown that these agents are able to reduce brain damage in stroke models and have synthesized an array of novel drug candidates with this activity. These agents target a class of cells in brain referred to as glial cells and they function to reduce the swelling of these cells (and the resultant brain swelling) that causes brain damage in stroke and head injury scenarios. The $100,000 grant will fund further development work on this novel approach to brain protection. Commenting on the announcement, Paul J. Marangos, Ph.D., CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Cypros and the principal investigator on the grant, said: "Glial cells have received very little attention as a target for drug development in the stroke and head injury area, yet we now know these cells are vital to nerve cell function and survival. "We are very excited about our novel prototype compounds and appreciate the scientific and financial support of the NIH to further develop these agents." Cypros Pharmaceutical is engaged in the development and marketing of drug products for the hospital market. The company is pursuing a diversified strategy of marketing approved drugs and developing small molecule therapeutics that protect cells from ischemic Ischemic An inadequate supply of blood to a part of the body, caused by partial or total blockage of an artery. Mentioned in: Antiangiogenic Therapy, Subarachnoid Hemorrhage, Ventricular Fibrillation ischemic injury. The company currently has three products on the market, Glofil, Inulin inulin /in·u·lin/ (in´ul-in) a starch occurring in the rhizome of certain plants, yielding fructose on hydrolysis, and used in tests of renal function. in·u·lin n. and Ethamolin. The company's CPC-111 and CPC-211 drugs are currently in Phase II clinical trials for a variety of cardiovascular and neurological disorders. This news release contains forward-looking statements which involve risks and uncertainties. Such statements are subject to certain factors which may cause the company's plans to differ. Factors that may cause such differences include, but are not limited to, the risks discussed in the company's Form 10-K for the fiscal year ended July 31, 1996, and the Risk Factors section of the company's registration statement No. 333-17501. CONTACT: Cypros Pharmaceutical Corp., Carlsbad David W. Nassif, 619/929-9500 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion